BioPharma Resources

Drug Trial Radar · NCT07860255

Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer

A Neoadjuvant Trial of Pasritamig in Unfavorable Intermediate to Very High-Risk Localized Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Nov 30, 2028

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Fred Hutchinson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Johnson & Johnson
First posted
Oct 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer. Pasritamig is a bispecific antibody that works by bringing immune cells called T cells close to prostate cancer cells that express KLK2, which may help the immune system attack the cancer. Giving pasritamig before radical prostatectomy may help researchers determine how the drug affects prostate cancer and the immune cells within the tumor.

Conditions

  • Prostate Cancer

Interventions

  • PasritamigDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility of neoadjuvant pasritamigTime frame: From first dose through radical prostatectomy, approximately 70 days
  2. Change in intratumoral CD3+ T-cell densityTime frame: Baseline to radical prostatectomy, approximately 70 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.